bioAffinity Technologies (BIAF) Revenue (2022 - 2026)

bioAffinity Technologies (BIAF) has 5 years of Revenue data on file, last reported at $1.4 million in Q1 2026.

• Revenue for Q1 2026 came in at $1.4 million, down 27.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (down 35.75% YoY), and the FY2025 annual result was $6.2 million, down 34.18% from the prior year.
• Revenue slipped to $1.4 million in Q1 2026 per BIAF's latest filing, from $1.6 million in the prior quarter.
• Over five years, Revenue peaked at $2.4 million in Q1 2024 and troughed at $921.0 in Q1 2023.
• A 5-year average of $1.2 million and a median of $1.4 million in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue soared 261180.24% in 2024, then tumbled 47.05% in 2025.
• A 5-year view of Revenue shows it stood at $2346.0 in 2022, then surged by 94245.95% to $2.2 million in 2023, then decreased by 0.26% to $2.2 million in 2024, then declined by 27.85% to $1.6 million in 2025, then declined by 15.15% to $1.4 million in 2026.
• Business Quant data shows BIAF's Revenue at $1.4 million in Q1 2026, $1.6 million in Q4 2025, and $1.4 million in Q3 2025.